Clinical Trials Logo

Solid Tumor, Adult clinical trials

View clinical trials related to Solid Tumor, Adult.

Filter by:

NCT ID: NCT05651022 Recruiting - Solid Tumor, Adult Clinical Trials

DECOY20 Study in Patients With Advanced Solid Tumors

Start date: February 28, 2023
Phase: Phase 1
Study type: Interventional

INDP-D101 is a Phase 1, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 in patients with locally advanced or metastatic solid tumors.

NCT ID: NCT05631899 Recruiting - Solid Tumor, Adult Clinical Trials

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Start date: April 3, 2023
Phase: Phase 1
Study type: Interventional

This is a pilot clinical trial for subjects with local advanced/metastatic solid tumors to determine the safety, efficacy and immune response of autologous EphA2-targeting CAR-DC vaccine loaded with KRAS mutant peptide (KRAS-EphA-2-CAR-DC) in combination with ICIs. It aims to: assess the safety and antitumor effects of KRAS-EphA-2-CAR-DC vaccine; detect T cell response against KRAS mutant peptide and tumor neoepitopes after the treatment with KRAS-EphA-2-CAR-DC vaccine and ICIs.

NCT ID: NCT05631886 Recruiting - Lymphoma Clinical Trials

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Start date: July 4, 2023
Phase: Phase 1
Study type: Interventional

This is a pilot clinical trial for subjects with local advanced/metastatic solid tumors or relapsed/refractory (R/R) lymphomas to determine the safety, efficacy and immune response of autologous EphA2-targeting CAR-DC vaccine loaded with TP53 mutant peptide (TP53-EphA-2-CAR-DC) in combination with ICIs. It aims to: assess the safety and antitumor effects of TP53-EphA-2-CAR-DC vaccine; detect T cell response against TP53 mutant peptide and tumor neoepitopes after the treatment with TP53-EphA-2-CAR-DC vaccine and ICIs.

NCT ID: NCT05607199 Recruiting - Clinical trials for Acute Myeloid Leukemia

A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics

BHARAT-1
Start date: September 16, 2022
Phase: Phase 1
Study type: Interventional

A Phase I, Open Label, Dose-Escalation, First in Human (FIH) study evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR103 Calcium in patients with relapsed advanced malignancies (BHARAT-1).

NCT ID: NCT05605197 Recruiting - Pancreatic Cancer Clinical Trials

U87 CART in Treatment of Advanced Solid Tumor

Start date: October 19, 2022
Phase: Phase 1
Study type: Interventional

This is a single center, open-label, phase 1 study to evaluate the safety and efficacy of U87 CART in treating advanced solid tumor .

NCT ID: NCT05605119 Recruiting - Hodgkin Lymphoma Clinical Trials

First in Human, Dose Escalation, Dose Expansion Study of AUR105

SURYA-1
Start date: November 30, 2022
Phase: Phase 1
Study type: Interventional

This is a multi-center, open-label, First in Human, Phase 1 study of AUR 105 in adult patients with advanced malignancies. The study will have two parts: a Dose Escalation Part and Dose Expansion Part.

NCT ID: NCT05601219 Recruiting - Solid Tumor, Adult Clinical Trials

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

Start date: November 15, 2022
Phase: Phase 1
Study type: Interventional

This study consists of dose escalation evaluation to determine the safety and tolerability of ADA-011 as a monotherapy and in combination with a checkpoint inhibitor. Following dose escalation, one or more dose expansion cohorts in selected indications will be explored to further evaluate the safety, tolerability, and preliminary efficacy of ADA-011.

NCT ID: NCT05597839 Recruiting - Solid Tumor, Adult Clinical Trials

Study of DF9001 in Patients With Advanced Solid Tumors

Start date: November 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible patients having selected solid tumors (monotherapy and in combination with pembrolizumab).

NCT ID: NCT05582850 Recruiting - Solid Tumor, Adult Clinical Trials

DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours

EPRAD
Start date: November 24, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multicentre, open-label, dose-escalation study to determine a recommended phase 2 dose (RP2D) of DT-9081, followed by an expansion study of DT-9081 in participants with advanced, recurrent or metastatic solid tumours

NCT ID: NCT05559541 Recruiting - Solid Tumor, Adult Clinical Trials

Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors

Start date: December 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase Ib/II Study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 combined with AK104 in tumor patients.